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combinations include crizotinib/EML4-ALK test in lung cancer; clopidogrel/CYP2C19 
test in cardiovascular disease; natalizumab/ JC virus test in multiple sclerosis; 
maraviroc/HIV tropism test in HIV infection. To define key evidence required by 
health technology assessment (HTA) agencies and payers for reimbursement and 
access decision making, we evaluated global CDx/biomarker test HTAs. Methods: 
HTA Watch conducted a search of global HTA agency websites for HTAs reviewing 
CDx/biomarker tests. HTAs were reviewed for key clinical, economic and other evi-
dence criteria scrutinized or raised as concerns by agencies, and potential impacts/
correlations of such evidence on agency reimbursement recommendations, distin-
guishing between true CDx and non-CDx biomarker tests. Results: CDx/biomarker 
tests reviewed by HTA agencies included those used to inform oncology, cardiovas-
cular or infectious disease, neurological disorder, and allergy/asthma treatments. 
Evidence scrutinized by HTA agencies included demonstration of clinical validity 
and utility versus competing tests or no test, cost-effectiveness and budget impact 
associated with implementing CDx testing, size of the responder population and, for 
solid tumor indications, the practicality of obtaining/availability of sufficient biopsy 
material for biomarker testing. ConClusions: CDx/biomarker tests are necessary 
gatekeepers for informing use of PM drugs, especially in early lines of treatment 
when alternative treatments exist. Since optimal PM market access requires CDx/
biomarker test availability it is critical that the value of CDx/biomarkers is demon-
strated through evidence development that addresses key HTA agency and payer 
needs.
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objeCtives: Severe respiratory infections result in infant hospitalizations for 
LRTI, of which the most common cause is due to respiratory syncytial virus (RSV). 
The economic impact of pediatric hospitalizations for respiratory infections is 
substantial; however the socioeconomic burden it has on parents and caregivers 
is less understood. Methods: Data was attained from the Parent Burden Study: 
A prospective multinational study to determine the humanistic and economic 
burden of infant LRTI hospitalizations during the RSV season. Direct health care 
resource utilization including length of hospitalization stay (LOS) and intensive 
care use (ICU) were obtained from medical chart reviews. Indirect economic 
burden borne by parents were measured in parent surveys administered at the 
time infants were discharged. Lost work productivity was assessed via the Work 
Productivity and Activity Impairment questionnaire, specific to caregivers of chil-
dren hospitalized with respiratory illness. Results: A total of 47 infants (35 term, 
12 preterm), < 1 year of age were included in the Parent Burden Study in Greece. A 
total of 74% of infants had a confirmed diagnosis of RSV. The mean LOS was 7.50 
days (range: 0.66- 40.97, 6.33 days term, 10.91 days preterm). 8.5% (2.9% term and 
25% preterm) required ICU admission and 85.1% had supplemental oxygen and/
or mechanical ventilation support (80% term, 100% preterm). Among fathers, the 
average absenteeism (time away from work) was 19.2%, presenteeism (impaired 
productivity while at work) was 45.6%, and overall work impairment was 55.3%. 
For mothers, the average absenteeism was 47.0%, presenteeism was 35.0% and 
overall work impairment was 54.0%. On average, fathers reported 62.1% activity 
impairment and mothers reported 93.5% due to their child’s hospitalization. A total 
of 51.1% of families required family or arranged childcare to assist siblings during 
the hospitalization. ConClusions: This study demonstrates, in addition to direct 
morbidity burden, infant LRTI hospitalizations have a substantial socioeconomic 
impact on parents and caretakers in Greece.
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objeCtives: Despite evidence of medication adherence benefits, many patients 
do not take their medications as prescribed. The objective of this study was to 
understand asthma medication treatment patterns among asthma patients in the 
US by initial asthma treatment medication. Methods: A retrospective database 
analysis was conducted using Marketscan Commercial and Medicare Supplement 
Data. Patients were identified between January 1, 2005 through March 31, 2011 based 
on asthma related hospitalization, emergency room visit or at least 2 office visits 
at different dates within 1 year. Asthma drug utilization patterns were analyzed 
among patients aged 12 years or older who were initiated on an asthma medica-
tion (without asthma maintenance therapy in the past 12 months) and had at least 
24 months traceable insurance coverage information since their initiation of the 
medication. Results: Among the selected patients (n= 88,567) being followed up 
for 24 months, approximately 30% of patients switched treatments at least once 
regardless of their initial asthma treatment. The three most common medications 
were montelukast sodium (> 90% Singulair), fluticasone propionate and salmeterol 
(Advair) 250/50mcg and 100/50mcg. One prevalent prescription change was to step 
down the steroid component. Patients initiating asthma treatment on combination 
therapy (i.e. Singulair and inhaled corticosteroids) is low (between 0.3% - 1.8%) and 
switch patterns show that over 50% of patients switch to Singulair monotherapy. 
Regardless of their initial treatment and medication switches, on average, asthma 
patients initiate their treatment with 2-3 months days supply; have a gap of over 6 
months (~200days) and switch to another treatment. ConClusions: Our results 
show the high frequency of asthma medication patterns changes. Despite the avail-
to indicators of asthma severity, control, health care utilization and comorbid-
ity. Results: A total of 661 QoL statements were identified from focus group 
transcripts and subsequently used to generate a pool of 112 items in 16 different 
content areas. Psychometric evaluation of field test data yielded a 65-item unidi-
mensional item bank, 4 and 12-item short forms (alpha = .86 and .93, respectively), 
and a simulated computer adaptive test suggesting that as few as 5-items are 
needed to obtain highly precise estimates of the impact of asthma on QoL (IAQL). 
Our measures correlated highly with Marks’ AQLQ and more strongly with the 
PROMIS global physical than mental scale. IAQL was greater in persons with indi-
cators of more severe asthma, less asthma control, and in persons with greater 
health care utilization. ConClusions: The RAND-IAQL item bank is a new freely 
available system for measuring the impact of asthma on Qol that will complement 
other patient-reported outcomes.
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objeCtives: Chronic obstructive pulmonary disease (COPD) is a major health 
problem in India and constitutes an important cause of mortality and morbid-
ity. A cross sectional study was undertaken to assess health related quality of life 
(HRQL) and its determinants in COPD patients from India. Methods: A total of 
126 patients (73.81% male, 26.19% female) recruited using convenient sampling in 
a cross-sectional study. Eligible patients assessed for socioeconomic status, anthro-
pometric measures, COPD severity, dyspnea, and health status using a validated 
Hindi (Regional Language) version of St. George Respiratory Questionnaire (SGRQ). 
Linear regression model was used to examine association between risk factors and 
HRQL with adjustment of age and sex. Results: Mean total score for SGRQ was 
52.66±12.89 showing marked impairment of HRQL. Impairment was associated with 
the severity of airway obstruction but within each GOLD stage the variation (SD) was 
wide [Stage I: 47.8±12.3 (n= 14); Stage II: 49.28±11.69 (n= 47); Stage III: 53.47±11.69 
(n= 44); Stage IV: 61.75±14.14 (n= 21)]. Regression analysis showed that body mass 
index, Forced expiratory volume in 1 minute (FEV1), dyspnea grade and depression 
were associated with poor HRQL. ConClusions: HRQL of COPD patients was sig-
nificantly impaired across all severities. Marked impairment of HRQL was found 
even in patients with milder disease.
ReSPiRatoRy-RelateD DiSoRDeRS – health care use & Policy Studies
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objeCtives: To provide an overview of the first experiences with reassessments 
and appraisals of expensive drugs after 4 years of coverage with evidence devel-
opment (CED) in The Netherlands. Methods: Completed assessments, reas-
sessments and appraisals were summarized. Special attention was paid to the 
consistency of the conclusions at the initial assessment (T= 0) with those at the 
reassessment (T= 4), to the execution of the research proposals, and to the con-
sequences of the reassessments and appraisals. Results: From 2006 until 2012, 
46 T= 0 assessments have been performed: 36 were approved for CED and 10 were 
declined. By mid 2013, the 4 years’ period of CED had ended for 25 drugs. For four 
drugs, T= 4 assessments and appraisals have been completed: omalizumab and 
ranibizumab for treatment of patients with severe asthma and macula degen-
eration respectively; and the orphan drugs alglucosidase alfa and agalsidase for 
treatment of patients with Pompe’s disease and Fabry’s disease. Based on all the 
available evidence, conclusions regarding effectiveness were mostly consistent 
between T= 0 and T= 4 assessments. However, results from the requested outcomes 
research studies between T= 0 and T= 4 were of mixed quality and therefore of lim-
ited relevance for the T= 4 assessment. Nevertheless, most data from the outcomes 
research were useful to evaluate appropriate usage in daily practice and resource 
use. The resource use data was applied in health economic models. In contrast, 
the input for the clinical effectiveness component in the cost-effectiveness assess-
ment was generally derived from pivotal clinical studies already available at T= 0. 
The T= 4 appraisals led to a societal debate on the cost-effectiveness of these 
drugs. The appraisals resulted in pragmatic solutions like a pay-for-performance 
agreement and ongoing price negotiations. ConClusions: Outcomes research as 
part of a CED in The Netherlands has yielded some information regarding the costs 
and appropriate use in daily practice of expensive drugs. The results from these 
CED experiments (or lack thereof) have been used in the subsequent negotiations 
on financial or risk-sharing arrangements.
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objeCtives: Personalized medicines (PM) are the subset of drug therapies whose 
efficacy and/or safety can be predicted or monitored based on the status of specific 
molecular biomarkers. In most cases, access to the applicable biomarker test (also 
called a companion diagnostic (CDx) if the biomarker/test is regulatory approved 
and included in the drug label) is critical for early patient access to the specific 
PM the biomarker status informs. Recent examples of PM and CDx/biomarker test 
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be averted. ConClusions: Price elasticity estimates are greater than previous 
studies in Greece and consistent with literature internationally, while income 
elasticity estimates are far greater. With cigarettes regarded as a luxury good, a 
great opportunity is presented for decison makers to counter smoking. Increased 
taxation, along with focused antismoking campaigns, law reinforcement (to ensure 
compliance with smoking bans) and intensive control for smuggling could inflict 
a massive blow to the tobacco epidemic in Greece.
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objeCtives: COPD is the third leading cause of death with increasing mortality 
while other chronic condition mortality rates are decreasing. This may be due to 
the fact that COPD is a complex chronic condition with a complicated diagnosis 
and treatment guideline in an aging patient population with increasing comor-
bid conditions. The objective of this study was to understand the prevalence of 
comorbid conditions among COPD patients in the US. Methods: A retrospective 
database analysis was conducted using Marketscan Commercial and Medicare 
Supplement Data from year 1/1/2010 to 12/31/2011. Patients were included if they 
had continuous medical and pharmacy benefits coverage for at least 12 months 
after their first COPD diagnosis defined as primary or ancillary ICD-9 codes of 
491.xx, 492.xx, or 496.xx and were between the ages of 40 and 90 years old at the 
time of diagnosis. Univariate descriptive analyses were conducted to quantify 
comorbid disease prevalence. Results: Among the selected patients (n= 231,827), 
95.1% (n= 220,519) had medical claims (ICD-9 codes) for diagnoses beyond COPD 
within 12 months of their COPD diagnosis. The majority of patients were over 65 
years old (61.4%, n= 135,366). Over 60% (n= 130,325) of the patients had more than 
3 comorbid conditions. The most common were hypertension (64.9%, n= 143,189) 
(ICD-9 codes 401.xx-405.xx, 415, 416, 416.8, 459.1x and 459.3x), hyperlipidemia 
(46.5%,n= 102,498) (ICD-9 code 272.x), diabetes (27.8%, n= 61,225) (ICD-9 code 249.xx, 
250.xx, 253.5, 271.4, 357.2, 588.1, 790.29), coronary artery disease (27.4%, n= 60,364) 
(ICD-9 code 414.0x, 414.3, 414.4), and asthma (22.7%, n= 50,113) (ICD-9 code 493.
xx). ConClusions: Our results show the significant prevalence of comorbid con-
ditions among COPD patients. Further research on comorbid conditions impacting 
COPD patient treatment adherence, COPD pathogenic pathways and worsening 
overall prognosis are necessary. More evidence is required to estimate the role of 
comorbidities in COPD.
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objeCtives: To examine the burden of illness of diagnosed obesity in the U.S. veteran 
population. Methods: A retrospective database analysis was performed using the 
Veterans Health Administration (VHA) Medical SAS datasets (01OCT2008-30SEPT2012). 
Patients diagnosed with obesity were identified (International Classification of 
Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis code 278.xx) with 
the first diagnosis date designated as the index date. A group of patients without 
obesity but with the same age, region, gender and index year were identified and 
matched by baseline Charlson Comorbidity Index as a comparator group. The index 
date for the comparator group was randomly chosen to reduce selection bias. Patients 
in both groups were required to be at least 18 years old, and have 1 year of continu-
ous medical and pharmacy benefits before and after the index date. Study outcomes, 
including health care costs and utilizations, were compared between the disease 
and comparator groups by using 1:1 propensity score matching. Results: A total 
of 1,525,218 patients were identified for the obesity and comparison cohorts. After 
applying 1:1 matching, a total of 634,257 of patients were included in each group, and 
the baseline demographic and clinical characteristics were balanced. The obesity 
cohort had higher percentages of health care utilizations for inpatient (6.21% vs. 
2.92%, p< 0.01), emergency room (11.96% vs. 7.28%, p< 0.01), physician office (99.84% vs. 
60.12%, p< 0.01), outpatient (99.86% vs. 60.85%, p< 0.01), and pharmacy visits (89.01% 
vs. 61.71%, p< 0.01) than the comparator group. Patients diagnosed with obesity 
also incurred higher expenditures in inpatient ($1,812 vs. $875, p< 0.01), emergency 
room ($117 vs. $69, p< 0.01), physician office ($2,936 vs. $1,436, p< 0.01), outpatient 
($3,288 vs. $1,621) and pharmacy visits ($641 vs. $423, p< 0.01) compared to non-obese 
patients. ConClusions: Study results suggest that patients diagnosed with obesity 
incurred significantly higher costs and utilizations than non-obese patients.
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objeCtives: To compare clinical efficacy and safety of orphan drug deferasirox 
(DSX) versus deferoxamine (DFO) in the treatment of paediatric patients (age ≤ 18 
years) with iron overload from repeated blood transfusions. The underlying con-
ditions requiring transfusion included beta-thalassaemia, sickle cell disease and 
other congenital and acquired anaemias (myelodysplastic syndromes, Diamond-
Blackfan syndrome, aplastic anaemia and other very rare anaemias). Methods: 
We searched CENTRAL, MEDLINE and EMBASE for relevant randomized controlled 
trials (RCTs) published up to April 2012. The review was conducted in accordance 
ability of prescription of asthma medications, there appears to be an unmet need 
and further research is necessary.
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objeCtives: To evaluate, compare, and assess the quality of the studies on the cost-
effectiveness of enhanced management (either as adjunct to usual care or alone) 
vs.usual care alone or none at all. Methods: Scientific databases (ScienceDirect, 
Wiley Online Library, (EbscoHost – MEDLINE, CINAHL, PSYInfo), (OvidSP – EMBASE, 
MEDLINE), and Scopus) were searched for published journal articles in English lan-
guage from year 1990 to 2012, using the search terms “asthma AND (intervene OR 
manage) AND (pharmacoeconomics OR economic evaluation OR cost effectiveness OR 
cost benefit OR cost utility)”. Hand search was done for local publishings. Only studies 
with full economic evaluation on enhanced management (either as adjunct to usual 
care or alone) were included. Selected studies were data abstracted and assessed for 
their quality of economic evaluation using the Quality of Health Economic Studies 
(QHES) instrument, and quality of evidence. Results: A total of 14 studies were 
included. There were three distinct modes reviewed: environmental control, self-
management, education. Most of the enhanced managements were found to be cost-
effective with ICER ranged from dominant to $26700.00 per unit of outcome. Overall, 
the mean score of QHES was 76.69% (SD 9.26). For the quality of evidence, ‘clinical 
effect sizes, adverse events & complication’, baseline clinical data, resourse use, and 
costs components were ranked mainly 1 or 2 (best or nearly best) in all studies. For 
‘utilities’ component, one study ranked 5 because it used visual analogue scale to 
obtain patient preference values. ConClusions: Despite the low qualities of the 
reviewed studies, it overall suggests that enhanced management (either as adjunct 
to usual care or alone) is mostly cost-effective than the usual care or none at all; 
environmental control is considered the most cost-effective, and there is also strong 
evidence for self-management, but provided the mode of it is made available, afford-
able, and accessible then this shall be worth to be adapted in one’s setting.
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objeCtives: Economic evaluation of the change in market dynamics of a sample 
ProductA1 through its inclusion in Therapeutic Equivalence Band (TEB) (with products 
B2 and C3) between 2010 and 2012 in Turkish health care system. Methods: IMS 
Dataview was analyzed for 2010-2012 unit sales values (market entry timeline for 
products A, B, C is 2006, 2009 and 2009, respectively) in the TEB. IMS Medical Index is 
used for estimating prescription data for the corresponding products. Assumptions on 
median patient adherence (receipt of prescribed treatment in pharmacy) are applied 
to prescription data in order to calculate unit sales (prediction). Deviation calcu-
lations and sensitivity analysis on market dynamics were performed in Microsoft 
Excel-2007. Results: Deviations between unit sales predictions and realizations 
for products A, B and C occurred as +11.48%, -5.41% and -20.85% in 2010, -10.16%, 
+8.14% and -53.87% in 2011 and -31.89%, +28.92% and -67.76% in 2012 respectively. 
Negative deviation values indicate that receipt of prescription cannot be transformed 
to receipt of the prescribed product in pharmacy, however positive deviation values 
correspond to receipt of a product in pharmacy which is different from the content of 
the prescription. ConClusions: The TEB system allows receipt of a different product 
than prescription. This study shows alteration of market dynamics in pharmacy as a 
change from prescribed inhaler option (as negative deviation value), which is linked 
to receipt of another inhaler option (as a positive deviation value) within the same 
TEB. Real life data may be collected for further analysis of TEB system in dynamics 
of corresponding market. 1Originator treatment in TEB-Novartis-Budesonide(400m
cg)&Formoterol(12mcg), 2Second treatment in TEB-Bilim Pharma, 3Third treatment 
in TEB-Abdi Ibrahim Pharma.
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objeCtives: Greece was long reported to show a smoking prevalence over 40% on 
adult population, as efforts to constrain smoking were rather ineffective. Following 
a sharp fall in cigarette consumption for 2012, our objective is to assess smokers’ 
sensitivity to cigarette price and consumer income changes as well as to project 
health benefits of an additional tax increase. Methods: Analysis includes the 
conventional model of demand, the myopic addiction model and the rational 
addiction model. Cigarette consumption for the period 1994-2012 was the depend-
ent variable with Weighted Average Price as a proxy for cigarette price, GDP as a 
proxy for consumer income and dummy variables reflecting smoking restrictions 
and antismoking campaigns. Values were computed to natural logarithms and 
regression was performed. Then, 4 scenarios of tax increase were distinguished in 
order to calculate potential health benefits. Results: Addiction models are una-
ble to provide statistically significant information following a nearly 23.5% drop 
in consumption during 2012. Short-run price elasticity is estimated at -0.441 and 
short-run income elasticity is estimated at 1.040. Antismoking campaigns were 
found to have a statistically significant impact on consumption. Results indicate 
that, depending on the level of tax increase, annual per capita consumption could 
fall by up to 607.99 cigarettes; tax revenue could rise by at least € 39 million, while 
up to 595,866 smokers could quit and up to 2,696 smoking related deaths could 
